SEMA3A and amyotrophic lateral sclerosis: Based on this bulk of evidence, we can conclude that hyperactive Sema3A signaling may be the leading cause of axonal degeneration and motoneuron death in ALS, making Sema3A a potential therapeutic target in this disease.